Urolithin A

A postbiotic metabolite produced by gut bacteria from dietary ellagitannins (pomegranate, walnuts, berries). Only 30–40% of humans harbor the gut bacteria required for conversion — direct supplementation (Mitopure) bypasses this microbiome lottery. The best-characterized natural mitophagy activator.

QUICK REF

• Evidence: 4/5 muscle endurance in ≥65 (1 Amazentis RCT, N=66). 4/5 muscle strength middle-aged (1 Amazentis RCT, N=90). 3/5 immune-aging T-cell fitness (new 2025 RCT). 3/5 recovery/inflammation biomarkers. 2/5 cognition / OA / liver / longevity (preclinical only). 1/5 heart failure (one negative RCT).
• Dose: 500 mg/day oral (cost-effective, achieves 400–800 nM Cmax). 1000 mg/day used in most positive RCTs. No added benefit above 1000 mg.
• Timing: Morning with food. Steady-state in 7–14 days; functional benefits at 4–8 weeks; peak at 12–16 weeks.
• Lab/Monitor: Not required in healthy adults. Optional: CRP, fasting glucose, creatinine at baseline + 3–6 mo.
• Key interactions: Avoid in organ transplant recipients (theoretical T-cell antagonism). No CYP450 or P-gp interactions.
• STATUS: CONDITIONAL — warranted for adults ≥60 with sarcopenia, frailty, or measurable mitochondrial decline. Marginal in healthy adults <50. Expensive ($60–180/mo) for evidence that is mostly single-sponsor and single-trial.

Clinical Summary

Urolithin A (UA) activates PINK1/Parkin-dependent mitophagy — the selective clearance of damaged mitochondria — and stimulates PGC-1α-driven mitochondrial biogenesis. In adults ≥65 with muscle weakness, 1000 mg/day for 4 months improved 6-minute walk distance by 17% (p=0.005) vs placebo [PMID 35050355]. In sedentary adults 40–65, the same dose improved leg-press strength by 12% and reduced CRP ~30% [PMID 35584623]. A 2025 RCT in middle-aged adults showed UA expanded less-exhausted naive-like CD8+ T cells and boosted their mitochondrial biogenesis and fatty-acid oxidation capacity — the first credible human immune-aging signal [PMID 41174221]. Evidence for cognition, Parkinson's, cardiovascular disease, liver disease, osteoarthritis, and cancer remains preclinical. The one human heart-failure RCT was negative [PMID 38415449].

Evidence pattern: Most positive human data comes from Amazentis-sponsored trials using proprietary Mitopure. Independent replication is sparse. No Phase 3 trial is registered as of 2026-04. FAERS is empty (UA never listed as suspect in 4 total reports — all concomitant). Long-term safety beyond 6 months is assumed based on mechanism and short-term tolerability but not formally established.

Key judgment: UA earns one clinically meaningful use-case — preserving muscle function in older adults with documented decline when paired with resistance exercise. All other indications are either too preliminary, too weakly replicated, or driven by surrogate endpoints. Distinguish this narrow utility from the Blueprint-protocol halo that pushes UA into stacks of healthy 30-somethings without evidence.

Indications & Evidence

Legend:

• Type codes: PC = Probabilistic Causal; UCC = Uncertain Causal Contribution; SE = Surrogate Endpoint; AHE = Animal-to-Human Extrapolation; FA = Failed Alternative (trial did not confirm benefit); NE = No Evidence.
• BH (Bradford Hill): /9 criteria met — Temporality, Strength, Consistency, Specificity, Dose-response, Plausibility, Coherence, Experiment, Analogy.
• Safety Flags: -- = no FAERS signal or safety concern (baseline for UA; FAERS has 4 total reports, all concomitant, zero suspect). MON = monitor relevant labs/clinical state. WARN = serious signal. AVOID = contraindicated.
• Star ceilings: PC ≤ 5/5 · UCC ≤ 4/5 · SE/BC ≤ 3/5 · ME/AHE ≤ 2/5 · FA/NE ≤ 1/5.

Prescribing

Form: Synthetic urolithin A identical to the natural metabolite. Oral capsules, softgels, or powder. Mitopure (Amazentis/Timeline) is the research-grade form used in all major RCTs. Generic UA from third-party-tested manufacturers is substantially cheaper but quality is uneven (Timeline's 2023 market-testing campaign alleged under-dosing in some Amazon products — self-serving but with partial third-party corroboration).

Dose:

• 500 mg once daily — cost-effective maintenance; achieves plasma Cmax 400–800 nM in nearly all users (bypassing the microbiome converter issue).
• 1000 mg once daily — dose used in positive RCTs. Marginal additional benefit on most endpoints. Preferred for frail elderly, immune-aging use, and the handful of active trials.
• Pomegranate extract and whole foods deliver ellagitannins but produce therapeutic UA only in Metabotype A individuals (~30–40% of population). No RCT has shown muscle or mitochondrial benefits from pomegranate-derived UA.

Route: Oral only. No clinical role for sublingual, transdermal, or injectable forms. Liposomal claims lack human PK or efficacy data.

Timing: Morning with food (10–15% AUC benefit and improved GI tolerance). Not an acute ergogenic — no value timing around workouts. Steady state reached in 7–14 days.

Onset: Biomarker changes (CRP, acylcarnitines) at ~4 weeks. Functional gains (strength, 6MWT) detectable at 8 weeks, peak at 12–16 weeks. Benefits fade over 2–4 weeks after stopping.

Cycling: Not required. No receptor desensitization; no tachyphylaxis in any published trial. Continuous daily dosing is the studied protocol.

Pharmacokinetics: Oral bioavailability 40–60% (direct supplement). Tmax 4–6 h. t½ 12–18 h with enterohepatic recirculation. Extensively glucuronidated (UGT1A9/1A8) and sulfated; conjugates retain tissue-level bioactivity via local deconjugation. Not a CYP450 substrate or inhibitor. Not a P-glycoprotein substrate.

Condition-Specific Protocols

Sarcopenia / Frailty in Older Adults (4/5)

Primary indication with the strongest human data.

• Dose: 1000 mg/day.
• Start: 500 mg/day × 2 weeks to assess tolerance, then 1000 mg.
• Pair with: Resistance exercise 2–3×/week. Liu 2022 showed the strongest functional gains in participants who remained active. UA without exercise produces biomarker changes without large functional translation.
• Duration: Minimum 4 months before deciding to continue. Clinical benefit should be visible as improved 6MWT, gait speed, grip strength, or chair-stand performance.
• Monitoring: Baseline and 3–6 month 6MWT or Short Physical Performance Battery (SPPB). Optional CRP.
• Stop if: No measurable functional improvement at 4 months despite compliance and activity.

Middle-Aged Adults with Mitochondrial Decline (4/5)

• Dose: 500–1000 mg/day. 1000 mg tracks Singh 2022 protocol.
• Best candidates: Sedentary 40–65 with elevated CRP, acylcarnitines, or subjective fatigue consistent with mitochondrial dysfunction.
• Duration: 4 months for meaningful evaluation.
• Pair with: Regular aerobic + resistance training. UA optimizes mitochondrial quality — training creates the demand that makes the improvement visible.

Athletic Recovery (Middle-Aged or Aging Athletes) (3/5)

• Dose: 500–1000 mg/day.
• Rationale: Whitfield 2025 (elite runners) showed no time-trial improvement but did show better recovery markers (CK AUC, RPE, VO2max trend). Benefit skews toward inter-session recovery rather than acute performance.
• Best candidates: Masters athletes, post-injury returnees, high-volume endurance blocks. Elite athletes with already-optimized mitochondria are unlikely to gain performance.
• Not a stimulant. Not pre-workout. Daily dosing independent of training.

Immune Aging / T-Cell Fitness (3/5 — new 2025 RCT, awaits replication)

• Dose: 1000 mg/day.
• Evidence: Denk 2025 (NCT05735886, MitoImmune) — 4 weeks expanded naive-like less-exhausted CD8+ T cells and boosted their fatty-acid oxidation [PMID 41174221]. Surrogate cellular endpoints; no infection or mortality outcomes yet.
• Best candidates: Adults 45–70 with subjective immunosenescence or low-grade inflammaging. Not ready for broad "immune support" marketing.

Safety

Adverse Effects

GI side effects occurred at similar rates in UA and placebo arms across all major RCTs (Andreux 2019, Singh 2022, Liu 2022), suggesting non-causal association.

FAERS Signal (via BioMCP, 2026-04)

Total reports mentioning UA or Mitopure: 4. UA listed as suspect drug: 0. All 4 reports list UA as concomitant while the primary suspect was relugolix, abatacept, a calcium/magnesium formulation, or estradiol. No indication-relevant reaction patterns. Consistent with the documented supplement-FAERS noise pattern: FAERS for supplements is dominated by concomitant-role reports without causal weight.

Contraindications / Cautions

• Pregnancy and lactation — avoid. No human safety data; animal teratology negative but human data absent. Whole-food ellagitannins (pomegranate, berries, walnuts) are safe alternatives for dietary ellagitannin intake.
• Pediatric (<18) — not recommended outside research. No data on developing mitochondrial systems.
• Organ transplant recipients on immunosuppression — avoid unless transplant physician clears. Preclinical data show UA enhances T-cell memory/function, which is directionally antagonistic to immunosuppression. Not tested in transplant populations.
• Severe renal impairment (GFR <30 mL/min) — use caution or avoid. Glucuronide conjugates are renally cleared; no PK data in advanced CKD. Reduce to 250–500 mg with monitoring if used.
• Active chemotherapy — discuss with oncologist. Mitophagy activation is theoretically antagonistic to chemotherapies that kill tumor cells via mitochondrial stress (e.g., platinums). No human oncology safety data outside the ongoing Phase 2 prostate trial (NCT06022822).
• Severe hepatic impairment (Child-Pugh C) — consider dose reduction to 250–500 mg.

Drug Interactions

Special Populations

• Elderly ≥75 — full standard dose (1000 mg) used in Liu 2022 without issue. Watch for paradoxical fall risk if activity level rises rapidly with improved strength; pair with physical therapy.
• Mild–moderate renal impairment (GFR 30–89) — standard dose generally acceptable; monitor creatinine/GFR at 3–6 months if CKD stage 3.
• Mild hepatic impairment (Child-Pugh A–B) — no adjustment needed; UA bypasses hepatic CYP metabolism.
• Autoimmune conditions — no specific contraindication; monitor disease activity. Avoid in organ transplant as above.
• Cancer survivors (off active treatment) — likely safe; may support recovery of healthy tissue. Standard dose.

Long-Term Safety

Longest published RCT exposure: 4 months continuous daily use. Animal NOAEL >1000 mg/kg/day (>70-fold safety margin over human therapeutic dose). No hepatic, renal, or cardiac toxicity signals. No tolerance or withdrawal. Long-term (>6 month) human safety is assumed but not formally established.

Synergies & Stacking

Clinically or mechanistically coherent combinations (note: no RCT has formally tested any UA combination):

• Creatine 3–5 g/day — Most common pairing. Non-overlapping muscle mechanisms: UA improves mitochondrial ATP-generation efficiency over months; creatine restores phosphocreatine for immediate ATP regeneration. Both have strong independent muscle evidence.
• Omega-3 (EPA/DHA) 1–2 g/day — Complementary anti-inflammatory pathways (UA via mitophagy/NF-κB; omega-3 via eicosanoids). Additive CRP reduction is plausible.
• CoQ10 (ubiquinol) 100–200 mg/day — Electron-transport support for the newly biogenic mitochondrial pool UA produces. Mechanistic, not yet trial-validated.
• NAD+ precursors (NMN, NR) 250–500 mg/day — UA clears damaged mitochondria; NAD+ fuels the healthy ones. Intuitive pairing but no human combination data.
• Vitamin D3 — Maintain serum 30–50 ng/mL for muscle anabolism baseline; the Liu 2022 sarcopenia effect size is likely amplified by adequate vitamin D status.
• Resistance exercise 2–3×/week — The most evidence-backed "synergy" — UA provides the cellular-level improvement that training translates into function.

No documented antagonism with minerals (Ca, Mg, Zn, Fe), fat-soluble vitamins (A, D, E, K), fiber, or common beverages (coffee, tea, alcohol). Not fat-soluble; meal fat content does not enhance absorption.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No commercial PGx panel guides UA dosing. The only meaningful individual modifier for direct supplementation is compliance.

Community & Anecdotal Evidence

DISCLAIMER — ANECDOTAL, NOT CLINICAL. This section reflects Reddit (r/Nootropics, r/Supplements, r/longevity, r/Biohackers), Longecity forum, YouTube biohacker channels, and Amazon/iHerb reviews. Sample sizes are approximate. None of it substitutes for RCT evidence. Treat as hypothesis-generating only.

Consensus Signals (N ≈ 200–400 aggregated user reports)

• Responder/non-responder split is large and obvious. Roughly half of posters report no subjective effect at any dose or duration; the other half report "deeper baseline energy," improved HRV, or faster workout recovery. This binary distribution is not typical of clinical RCT populations, where averaged effects can mask individual responder patterns.
• Best subjective reports come from deconditioned or post-illness users rebuilding from a low baseline — likely genuine signal plus regression-to-mean and selection bias.
• Trained athletes report minimal acute effect — matches the Whitfield 2025 elite-runner negative performance data.

Reported Effects Inventory

Community Dosing vs Clinical Dosing

Red Flags & Skepticism Notes

• Amazentis/Timeline owns the evidence base. Most published human RCTs are company-sponsored. Independent replication is limited. This is not a reason to dismiss the data but is a significant bias-weighting factor.
• Bryan Johnson Blueprint halo drives adoption beyond what evidence warrants. "Bryan takes it" is a social-proof argument, not a clinical one; Blueprint is an uncontrolled n=1 protocol that cannot attribute any single effect to UA.
• Thomas DeLauer and similar YouTube coverage includes Timeline Mitopure with inconsistent sponsorship disclosure.
• "It works at the cellular level even if you don't feel it" — the marketing fallback when a user reports no effect. Unfalsifiable framing is a yellow flag even when mechanistically true.
• Timeline's 2023 "generic UA is fake" campaign was partially corroborated by third-party testing but also served the incumbent's commercial interest. Purity is a real issue; the messenger is conflicted.
• No MLM structure, no pyramid/referral system, and community skepticism is uncensored on Reddit — non-responder reports survive, which argues against organized astroturfing.

Folk vs Clinical Reality Check

The community's strongest anecdotal claim — muscle recovery — aligns with the strongest clinical finding (Liu 2022 endurance, Whitfield 2025 recovery markers, Zhao 2024 strength). The community's weakest signal — "no effect" in many users — aligns with the Whitfield 2025 negative time-trial result in elite athletes and the responder/non-responder pattern implicit in Singh 2022 effect-size variance. The community's enthusiasm for cognition, skin, and longevity outruns the evidence.

Deep Dive

Mechanism

UA's core activity is selective mitophagy — the autophagic degradation of damaged mitochondria — via the PINK1/Parkin pathway. PINK1 accumulates on depolarized outer mitochondrial membranes, recruits the E3 ubiquitin ligase Parkin, and tags defective mitochondria for autophagosomal engulfment. UA enhances this process preferentially in cells with mitochondrial stress, leaving healthy mitochondria intact.

Mitophagy is coupled to mitochondrial biogenesis via PGC-1α, NRF1, and NRF2 signaling. The net effect is improved mitochondrial quality rather than raw increase in number — a more functionally efficient electron-transport chain, reduced ROS, and lower inflammatory signaling through NF-κB.

Mechanistic discoveries 2024–2026 extend UA's reach beyond classical PINK1/Parkin:

• Lysophagy via cathepsin Z restores lysosomal function in Alzheimer's models [PMID 38753870].
• cGAS-STING modulation — UA-driven mitophagy clears cytosolic mtDNA that would otherwise drive cGAS/STING-mediated neuroinflammation [PMID 38280852, 2024 Nat Commun, now heavily cited].
• ERK1/2-ULK1 axis in CD8+ T cells drives the immune-aging phenotype seen in Denk 2025 [PMID 38447147].
• SIRT1/PER2 circadian amplification in senescent cells [PMID 39796454].
• AMPK/CREB/BDNF pathway activation underlies preclinical antidepressant signals [PMID 40732919].
• Enterocloster dehydroxylase identified as the specific human gut bacterial enzyme producing UA from ellagitannins [PMID 39856097, Nat Commun 2025] — finally resolves the microbiome-converter biology mechanistically.

UA is not a CYP450 substrate, not a hormone-receptor agonist, and not a classical antioxidant. It is a gene-expression modulator acting through mitochondrial-quality-control pathways.

Pharmacokinetics

• Oral bioavailability of direct UA: 40–60%.
• Tmax 4–6 h; t½ 12–18 h; steady-state in 7–14 days.
• Plasma forms: 5–15% free UA, 70–80% glucuronides, 10–20% sulfates.
• Enterohepatic recirculation via bacterial β-glucuronidase deconjugation extends effective half-life.
• Plasma Cmax: ~250–400 nM (250 mg), ~400–800 nM (500 mg), ~800–1200 nM (1000 mg). Inter-individual CV ~20–25% with direct supplementation vs ~300% with dietary sources.
• Crosses the blood-brain barrier (preclinical); human CSF PK trial (NCT07517913) not yet recruiting as of 2026-04.

Clinical Trials Summary (2026-04)

No Phase 3 UA trial is registered by any sponsor.

Regulatory Status

• FDA GRAS: Mitopure received No Objection letter GRN 791 (2018) for synthetic UA up to 1000 mg/day.
• EU EFSA: Authorized as Novel Food under Commission Implementing Regulation (EU) 2021/1377 — up to 1000 mg/day for adults, 250 mg/day in specific food categories.
• Swiss BLV: Classified as novel food.
• UK FSA: Submission 2022-10-25.
• WADA: Not on the prohibited list (2026). Athletes subject to testing should prefer NSF Certified for Sport products to avoid contamination.
• No FDA/EMA drug approval — UA is a food ingredient, not a drug.

Systematic Reviews

• Kuerec 2024 (Ageing Res Rev, PMID 39002645) — first systematic review of human UA trials. Concludes benefits on muscle endurance and mitochondrial biomarkers; limited or absent effects on ATP production or microbiota composition.
• Francisco 2026 (Oncol Res, PMID 41646627) — UA in colorectal cancer; preclinical-dominant.
• Yuan 2026 (PMID 41866331) — bioavailability review; revises non-producer estimate toward ~10% (vs earlier 30–40%) when measured as complete non-conversion independent of age.

No formal meta-analysis exists — evidence is too heterogeneous across indications.

Ataraxia Verdict (as of 2026-04-17)

Hype Check

• "Natural safety" — UA is endogenously produced in 30–40% of humans from dietary precursors, which argues for metabolic tolerability but does not establish supra-physiological-dose safety. The 1000 mg direct supplement produces plasma levels ~5–10× what the gut microbiome achieves from diet.
• "Clinically proven" — positive trials exist but are dominated by one sponsor. Independent replication is limited; no Phase 3; no meta-analysis. The honest framing is "human-validated with moderate evidence in narrow indications."
• "Mitophagy = longevity" — the leap from mitophagy activation in C. elegans to human healthspan is mechanistically plausible but speculative in humans. Calling UA "the longevity supplement" oversells what any current human data supports.
• Bryan Johnson / Blueprint halo — social proof, not evidence. Blueprint is uncontrolled; UA cannot be attributed as the driver of any specific Blueprint outcome.

Evidence Classification

• Muscle endurance in sarcopenia (≥65): PC, BH 5/9 — one high-quality RCT, functional endpoint, clinically meaningful effect size. Ceiling 5/5; actual 4/5 pending replication.
• Muscle strength (middle-aged): PC, BH 4/9 — single trial, same sponsor. 4/5.
• Recovery markers (athletes): PC, BH 4/9 — replicated across Whitfield 2025 and Zhao 2024 directionally. 3/5.
• Resistance-training performance (young trained males): PC, BH 3/9 — Zhao 2024 positive but small, single-blinded. 3/5.
• Immune-aging T-cell fitness: UCC, BH 3/9 — novel signal, cellular endpoints (not infection or mortality outcomes), sponsor-funded. 3/5.
• CRP / inflammation: SE, BH 4/9 — the surrogate-endpoint trap applies. CRP reduction is biologically plausible but has historically over-predicted clinical benefit (see vitamin E precedent). Ceiling 3/5.
• Mitochondrial biomarkers (acylcarnitines, muscle gene expression): SE, BH 3/9 — mechanism-confirming but not outcome-confirming. Ceiling 3/5.
• OA / cognition / Parkinson's / liver / cancer / longevity: AHE, BH 1–2/9 — preclinical only; human data absent. Ceiling 2/5.
• Heart failure: FA, BH 2/9 — one negative trial; do not use for this. 1/5.
• Skin / hair / bone / blood sugar: NE — no human data in the oral use case. 1/5.

Evidence Gaps

• No Phase 3 trial registered by any sponsor as of 2026-04.
• No formal meta-analysis (evidence too heterogeneous).
• No long-term (>6 month) safety RCT — long-term tolerability is assumed but not formally established.
• No cognitive, Parkinson's, or dementia human efficacy trial published. Several preclinical mechanisms, zero human outcome data.
• No sex-stratified efficacy analysis in mixed-sex trials. Several RCTs are male-only.
• No independent (non-Amazentis) replication of the sarcopenia or middle-aged strength effect.
• No head-to-head vs creatine, HMB, spermidine, NMN, or PQQ.
• CSF penetration in humans not yet measured (NCT07517913 pending).
• Converter-status stratified efficacy of dietary-derived UA in RCTs — Li 2025 mouse stratification is the only concrete experimental converter-stratified data [PMID 40171675].

Bias Flags

• Sponsor concentration. Amazentis funds most human RCTs, supplies the product used in most RCTs, and publishes with its founding scientists as authors. Sponsor bias is real and unresolved.
• Positive-trial overweighting in public discourse. Liu 2022 and Singh 2022 dominate citation; Jamialahmadi 2024 (negative HF) and Whitfield 2025 (negative performance) receive less attention.
• Surrogate-endpoint trap. Many "benefits" are biomarker improvements (CRP, acylcarnitines, muscle gene expression) that do not automatically translate to clinical outcomes. Historical precedent (vitamin E, antioxidants, CETP inhibitors) argues for caution.
• Selection bias in trial populations. Liu 2022 recruited adults with documented functional decline — the population with the most to gain. Effect sizes may not translate to robust older adults.
• Publication lag for null results. NCT06556706 (frail elderly N=26) completed April 2025 with results "pending." Absence of prompt publication is a soft signal.

Manipulation Flags

• Premium pricing of Mitopure ($75–180/mo) vs generic UA ($20–40/mo) is not fully justified by purity differences. Mitopure has verified quality and was used in all major RCTs; this earns a legitimate premium but not a 3–5× one.
• Timeline's 2023 "generic is fake" campaign served a commercial interest and should be weighted accordingly even where technically accurate.
• Influencer economics — coverage by Thomas DeLauer and similar YouTube channels features Timeline Mitopure with inconsistent sponsorship disclosure. Peter Attia and Rhonda Patrick discuss mitochondrial health broadly; neither has a confirmed Timeline sponsorship but both indirectly elevate the category.
• Bryan Johnson halo functions as organic marketing without Amazentis paying for it — still a manipulation effect on public perception.
• "Works at the cellular level" rebuttal to non-responders is unfalsifiable framing.
• Pharma has no competing product, so there is minimal motive for organized anti-UA fearmongering. Cui bono runs mostly one direction (pro-UA marketing).
• Red team (10 angles):
  1. Logical consistency — mitophagy activation → mitochondrial function → physical performance is coherent but each link is probabilistic.
  2. Evidence quality — moderate for muscle endurance; weak for most other claims.
  3. Cui bono pro-UA — Amazentis, Timeline retailers, Blueprint-adjacent influencers.
  4. Cui bono anti-UA — minimal; no competing pharma product.
  5. Time horizon — benefits take months, costs are immediate and ongoing.
  6. Steelman — UA is the first scalable, PK-predictable mitophagy activator in humans with any functional RCT data.
  7. Reversibility — fully reversible; discontinuation restores baseline within 2–4 weeks.
  8. Second-order effects — if UA becomes standard of care for sarcopenia, exercise interventions may be under-prescribed (supplement displaces activity).
  9. Historical precedent — biomarker-improving supplements (vitamin E, CoQ10 for CVD, beta-carotene) have a mixed record translating to outcomes.
  10. Stranger test — would recommend to an older relative with documented weakness + willingness to train; would not recommend to a healthy 30-year-old with no complaint.

Decision Support (Clarity Compass)

• Health utility score: 5/10. One evidence-supported narrow indication (sarcopenia/frailty), several probable but under-replicated indications (middle-aged strength, immune aging, recovery), and a large basket of preclinical claims. Evidence concentration in one sponsor caps the score.
• Opportunity cost: High financial cost ($60–180/month ongoing). Low complexity cost (single daily capsule). Moderate attention cost — benefits are slow and invisible, easy to rationalize continuation without checking endpoints.
• Hell Yes or No: No. The evidence does not support an enthusiastic universal yes. It supports a targeted yes for a specific population.
• Regret minimization: In 5 years, more independent trials and long-term safety data will exist. Starting now is low-regret only if matched to a population with documented need; starting now speculatively for "longevity" in a healthy 30-year-old is likely to be looked back on as premature.
• Verdict: CONDITIONAL.
  • Warranted: Adults ≥60 with documented sarcopenia, frailty, or functional decline, paired with resistance exercise; or adults 40–65 with elevated inflammatory markers and mitochondrial-dysfunction-pattern fatigue.
  • Reasonable trial: Masters athletes prioritizing recovery; adults 45–70 with interest in immune-aging modulation willing to accept single-trial evidence.
  • Skip: Healthy adults <50 with no specific indication; elite athletes expecting acute performance; anyone using it as a general "longevity supplement" without a concrete endpoint.

Bottom Line

UA has graduated from "interesting mechanism" to "narrow but real human effect" in older adults with muscle decline. That is the one clinically defensible use-case. Everything else — cognition, cardiovascular, liver, cancer, longevity, skin — remains preclinical or too preliminary to justify the cost. The evidence base is sponsor-concentrated; wait for independent Phase 3 replication before broadening the indication list. For the right person at the right age with the right complaint, it is a reasonable tool. For the Blueprint-copycat healthy 30-year-old, it is overpriced placebo insurance against a problem they do not yet have.

Practical Notes

• Brands: Mitopure (Timeline Nutrition / Amazentis) for research-grade, NSF Certified for Sport. Generic alternatives (Nootropics Depot, Double Wood, Renue by Science) at lower cost — verify Certificate of Analysis (≥98% UA, heavy metals <5 ppm, microbial limits). Avoid unverified Amazon listings; Timeline's 2023 purity-testing campaign was self-serving but raised legitimate concerns about generic under-dosing.
• Storage: Room temperature, dry, protected from direct sunlight. Shelf life ~24 months unopened, 12–18 months after opening. Liposomal forms may require refrigeration.
• Palatability: Capsules or softgels are neutral; powders are near-flavorless with slight bitterness and mix moderately well in smoothies or yogurt. Avoid mixing into hot beverages (theoretical degradation risk, unquantified).
• Exercise timing: Irrelevant to training sessions. Daily dosing, morning with food, regardless of workout schedule.
• Circadian: Morning dosing aligns with circadian peaks of PGC-1α and mitochondrial biogenesis. No head-to-head AM vs PM trial.
• Reference ranges: UA is not measured in routine clinical labs. Research-grade plasma targets: Cmax 400–800 nM (therapeutic), trough 100–300 nM steady-state. Tissue levels ~50–100× lower than plasma in muscle biopsy studies.
• Cost: Mitopure 500 mg ~$75–105/month; Mitopure 1000 mg ~$165–180/month; Generic 500 mg ~$60–75; Generic 1000 mg ~$120–135. Pomegranate extract $15–30/month but delivers reliable UA only in the ~30% producer subset.
• WADA / drug-testing: UA is not on the 2026 prohibited list. Athletes subject to testing should use NSF Certified for Sport-labeled product to avoid cross-contamination risk.

What We Don't Know

• Whether the Liu 2022 and Singh 2022 effect sizes replicate in non-Amazentis-sponsored RCTs.
• Long-term (>6 month, ideally >2 year) efficacy and safety in any indication.
• Whether any non-muscle indication (cognition, Parkinson's, liver, cardiovascular, cancer) produces clinically meaningful human outcomes.
• Whether CSF penetration in humans reaches pharmacologically relevant levels (NCT07517913 pending).
• Sex-specific dose-response — most trials under-stratify.
• Whether UA is useful in active chemotherapy (theoretical antagonism vs possible synergy with immune checkpoint inhibitors — NCT07161310 ongoing).
• Head-to-head efficacy vs creatine, HMB, spermidine, NMN, or PQQ.
• Whether the generic vs Mitopure purity gap is real in 2026 after Timeline's public testing campaign.
• Whether adding UA to a sarcopenia protocol adds more than resistance exercise alone (Liu 2022 encouraged activity in both arms but did not isolate the training × UA interaction).
• Whether converter-status testing (stool or metabolite panel) should become clinical practice before prescribing pomegranate extract as a substitute.

References

Human RCTs

1. Liu S et al. (2022) — Urolithin A supplementation on muscle endurance and mitochondrial health in older adults. JAMA Network Open 5(1):e2144279. PMID 35050355.
2. Singh A et al. (2022) — UA improves muscle strength, exercise performance, and biomarkers of mitochondrial health, middle-aged adults. Cell Reports Medicine 3(5):100633. PMID 35584623.
3. Andreux PA et al. (2019) — First-in-human safety and molecular signature study. Nature Metabolism 1(6):595–603. PMID 32694802.
4. Singh A et al. (2022) — Direct supplementation overcomes dietary exposure and microbiome variability. Eur J Clin Nutr 76(2):297–308. PMID 34117375.
5. Jamialahmadi T et al. (2024) — UA in heart failure with reduced EF. Rev Recent Clin Trials 19(3):221–228. PMID 38415449. (Negative trial.)
6. Whitfield J et al. (2025) — UA in highly trained male distance runners. Sports Medicine. PMID 40839339. (No performance gain; recovery markers improved.)
7. Zhao H et al. (2024) — UA in resistance-trained males. J Int Soc Sports Nutr. PMID 39487653.
8. Denk D et al. (2025) — UA expands naive-like CD8+ T cells in middle-aged adults (MitoImmune). Nature Aging. PMID 41174221. (Correction: PMID 41491872.)
9. Monsalve Acevedo A et al. (2025) — UA in academy soccer players. Front Nutr. PMID 41245402.

Systematic Reviews

10. Kuerec AH et al. (2024) — Targeting aging with UA in humans: a systematic review. Ageing Res Rev 100:102406. PMID 39002645.
11. Francisco M et al. (2026) — UA in colorectal cancer: systematic review. Oncol Res. PMID 41646627.
12. Yuan H et al. (2026) — UA bioavailability and converter-status review. PMID 41866331.

Mechanism & Preclinical

13. Ryu D et al. (2016) — UA induces mitophagy and prolongs lifespan in C. elegans; improves rodent muscle function. Nature Medicine 22(8):879–88. PMID 27400265. (Foundational preclinical.)
14. D'Amico D et al. (2022) — UA reduces cartilage degeneration in osteoarthritis models. Aging Cell 21(8):e13662. PMID 35778837.
15. Denk D et al. (2022) — UA expands T memory stem cells and enhances antitumor immunity (preclinical). Immunity 55(11):2059–2073. PMID 36351375.
16. Pidgeon R et al. (2025) — Enterocloster dehydroxylase produces UA in human gut. Nature Communications 16(1):999. PMID 39856097.
17. García-Villalba R et al. (2022) — Comprehensive urolithin metabolism review. Mol Nutr Food Res 66(21):e2101019. PMID 35118817.
18. Zhang M et al. (2023) — Ellagic acid and UA metabolism review. Crit Rev Food Sci Nutr 63(24):6900–6922. PMID 35142569.
19. D'Amico D et al. (2021) — UA on health, disease, and aging. Trends Mol Med 27(7):687–699. PMID 34030963.

Mechanism Discoveries 2024–2026

20. Cathepsin Z / lysophagy in AD (2024). PMID 38753870.
21. cGAS-STING mtDNA regulation (2024, Nat Commun). PMID 38280852.
22. ERK1/2-ULK1 in CD8 antitumor immunity (2024, Adv Sci). PMID 38447147.
23. TFEB in breast cancer macrophages (2024, J Adv Res). PMID 38615740.
24. AMPK/CREB/BDNF antidepressant mechanism (2025). PMID 40732919.
25. SIRT1/PER2 circadian modulation in senescent cells (2024). PMID 39796454.
26. GLS1 / glutaminolysis in cirrhosis (2024). PMID 39038605.
27. Calcium-dependent mitophagy / aging (2025, Autophagy). PMID 40944367.
28. PDE4 inhibition in RPE (2025). PMID 40983836.
29. NAFLD differential response by converter status (2025, mice). PMID 40171675.

Cross-Indication Preclinical (selected)

30. Parkinson's cognitive-impairment rescue (mice). PMID 40714019.
31. Ovarian reserve protection (mice). PMID 40723388.
32. Sepsis-induced muscle dysfunction (mice). PMID 40817441.
33. Peripheral nerve regeneration. PMID 41172819.
34. Atherosclerosis (mice). PMID 38886550.
35. Rheumatoid arthritis preclinical. PMID 40215775.
36. Kidney stone disease (PCK1). PMID 41265017.
37. Sarcopenia + gut microbiota SR. PMID 39142365.
38. Postbiotics and obesity SR. PMID 39461594.

Regulatory / External

• FDA GRAS Notice GRN 791 — Mitopure up to 1000 mg/day (2018).
• EU Commission Implementing Regulation (EU) 2021/1377 — UA as novel food.
• ClinicalTrials.gov: ~27 unique registered UA / Mitopure trials as of 2026-04; no Phase 3.